Evidence map›Paper›PMID 38063383›Full record

ArticleMicrobiology spectrum2024

Can antimicrobial blue light contribute to resistance development? Genome-wide analysis revealed aBL-protective genes in

Beata Kruszewska-Naczk, Mariusz Grinholc, Krzysztof Waleron, Julia Elisabeth Bandow, Aleksandra Rapacka-Zdończyk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Beata Kruszewska-NaczkLaboratory of Photobiology and Molecular Diagnostics, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk , Gdansk, Poland.
Mariusz GrinholcLaboratory of Photobiology and Molecular Diagnostics, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk , Gdansk, Poland.
Krzysztof WaleronDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Medical University of Gdansk , Gdansk, Poland.
Julia Elisabeth BandowApplied Microbiology, Faculty of Biology and Biotechnology, Ruhr University Bochum, Universitätsstraße , Bochum, Germany.ORCID 0000-0003-4100-8829
Aleksandra Rapacka-ZdończykDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Medical University of Gdansk , Gdansk, Poland.ORCID 0000-0002-7611-0359

Funding

Narodowe Centrum Nauki (NCN) 2020/36/C/NZ7/00061
6 · The paper itself

Abstract

importanceIncreasing antibiotic resistance and the lack of new antibiotic-like compounds to combat bacterial resistance are significant problems of modern medicine. The development of new alternative therapeutic strategies is extremely important. Antimicrobial blue light (aBL) is an innovative approach to combat multidrug-resistant microorganisms. aBL has a multitarget mode of action; however, the full mechanism of aBL antibacterial action requires further investigation. In addition, the potential risk of resistance development to this treatment should be considered.

Indexed as

Anti-Infective AgentsEscherichia coliAnti-Bacterial AgentsBlue LightDrug Resistance, MicrobialMicrobial Sensitivity TestsAnti-Bacterial AgentsAnti-Infective Agentsantimicrobial blue lightEscherichia coligenome-wide analysishypersensitive mutantsresistance

Identifiers

PMID38063383
PMCPMC10782963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.